Q3 2025 Management View CEO Shankar Musunuri highlighted the company's rapid progress on its modifier gene therapy platform, noting "in just over 3 years, we brought our lead candidate, OCU400, from ...

The government has extended financial support to ImmunoAct to expand gene delivery systems, making breakthrough cancer treatments more affordable. Clinical trials of CAR-T therapy have been promising ...

Pfizer and Novo Nordisk continue to fight for ownership of obesity startup Metsera; CDER Director George Tidmarsh leaves his ...

Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced that it has ...

Pluristyx's iPSC platform provides therapeutic developers with a streamlined path from research to clinical application, offering high-quality, regulatory-compliant starting materials and advanced ...

Ocugen has scheduled a conference call and webcast for 8:30 a.m. ET today to discuss the financial results and recent business highlights. Ocugen’s senior management team will host the call, which ...

The MarketWatch News Department was not involved in the creation of this content.-- Third quarter revenue increased 15% year-over-year to $44.2 million -- Commercial Cell & Gene T ...

The agency is establishing a network of care centers to expand access to regenerative medicine beyond regions served by major ...

Vancouver, Canada, November 4th, 2025, FinanceWire Equity Insider News Commentary – The precision medicine sector reached ...

UniQure shares soared on positive AMT-130 Huntington's disease data, but plunged after the FDA reversed its stance on ...

The potential approval of Vertex’s IgAN therapy povetacicept in 2026 comes amid launch headwinds for the company’s non-opioid ...

In a world first, a bespoke gene-editing therapy benefited one child. Now researchers plan to launch a clinical trial of the approach ...